SCHEMBL267318

SCHEMBL267318

Cc1cccc(C=NNC(=O)c2cc(Br)ccc2NC(=O)c2ccc(CSc3cccc(F)c3)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.53
RAB9A P51151 3/20 0.53
ALDH1A1 P00352 2/20 0.47
SLC34A2 O95436 1/20 0.47
SLC34A1 Q06495 1/20 0.47
SLC34A3 Q8N130 1/20 0.47
SLC20A1 Q8WUM9 1/20 0.47
TDP1 Q9NUW8 3/20 0.44
POLB P06746 2/20 0.44
PLEC Q15149 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
HTT P42858 2/20 0.42
MAPT P10636 1/20 0.42
NPC1 O15118 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
GUSB P08236 1/20 0.41
MEN1 O00255 6/20 0.41
KMT2A Q03164 6/20 0.41
HPGD P15428 3/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL274182 1.00 SMN1; SMN2 (0.53) SMN1; SMN2RAB9AALDH1A1SLC34A2SLC34A1
SCHEMBL267884 0.88 RAB9A (0.54) SMN1; SMN2RAB9AALDH1A1TDP1POLB
SCHEMBL274090 0.88 RAB9A (0.54) SMN1; SMN2RAB9AALDH1A1TDP1POLB
SCHEMBL274087 0.87 SLC34A2 (0.49) SMN1; SMN2RAB9AALDH1A1SLC34A2SLC34A1
SCHEMBL266207 0.87 SLC34A2 (0.49) SMN1; SMN2RAB9AALDH1A1SLC34A2SLC34A1
SCHEMBL267875 0.86 SMN1; SMN2 (0.64) SMN1; SMN2RAB9AALDH1A1TDP1POLB
SCHEMBL267876 0.86 SMN1; SMN2 (0.64) SMN1; SMN2RAB9AALDH1A1TDP1POLB
SCHEMBL268485 0.85 SMN1; SMN2 (0.52) SMN1; SMN2RAB9AALDH1A1SLC34A2SLC34A1
SCHEMBL268486 0.85 SMN1; SMN2 (0.52) SMN1; SMN2RAB9AALDH1A1SLC34A2SLC34A1
SCHEMBL265400 0.84 SMN1; SMN2 (0.56) SMN1; SMN2RAB9AALDH1A1SLC34A2SLC34A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SMN1; SMN2 3975/4885RAB9A 883/4885ALDH1A1 3022/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SMN1; SMN2 4253/4885RAB9A 1362/4885ALDH1A1 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.